Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis |
| |
Affiliation: | 1. Evidera, The Ark, 201 Talgarth Road, London W6 8BJ, United Kingdom;2. Pfizer Inc., 235 42nd Street, New York, NY 10017, United States |
| |
Abstract: | Pneumococcal disease is a substantial contributor to illness and death in young children globally. The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 had a significant impact in preventing pneumococcal disease in both vaccinated children and unvaccinated individuals (through herd effect). A higher valent PCV13 replaced PCV7 in late 2009. This analysis was undertaken to assess how many cases and deaths have been averted over the last decade since PCV13 introduction. A model estimated the number of infants vaccinated annually with PCV13, as well as the number of cases and deaths of invasive pneumococcal disease, pneumococcal pneumonia, and acute otitis media cases averted.PCV13 vaccination was estimated to have prevented 175.2 million cases of all pneumococcal diseases and 624,904 deaths globally between 2010 and 2019. These results demonstrate the substantial public health impact of PCV13 and highlight the importance of increasing the global reach of PCV programs. |
| |
Keywords: | Burden Children Pneumococcal disease Pneumococcal pneumonia Public health impact Vaccination |
本文献已被 ScienceDirect 等数据库收录! |
|